|
Patent landscape, scope, and claims: |
Analysis of United States Patent 5,558,083: CGRP Receptor Antagonists
This report analyzes United States Patent 5,558,083, covering calcitonin gene-related peptide (CGRP) receptor antagonists. The patent, assigned to Amgen Inc., was granted on September 24, 1996. It claims compounds that inhibit the binding of CGRP to its receptor and their use in treating CGRP-mediated conditions, primarily migraine.
What is the Core Invention of Patent 5,558,083?
The central invention of U.S. Patent 5,558,083 is a class of small molecule compounds that act as antagonists to the calcitonin gene-related peptide (CGRP) receptor. These compounds are designed to block the biological activity of CGRP, a neuropeptide implicated in the pathophysiology of migraine headaches.
The patent claims encompass:
- Specific Chemical Structures: The patent details a general chemical formula for the claimed compounds, including definitions for various substituents (R1, R2, R3, R4, R5) that allow for a broad range of molecular variations.
- Therapeutic Use: The primary therapeutic application disclosed is the treatment of migraine headaches. The mechanism of action is the inhibition of CGRP binding to its receptor, thereby preventing vasodilation and neurogenic inflammation associated with migraine.
- Pharmaceutical Compositions: The patent also claims pharmaceutical compositions containing these CGRP receptor antagonists, along with pharmaceutically acceptable carriers, for use in treating CGRP-mediated disorders.
The disclosed synthesis routes and characterization data for representative compounds are provided, demonstrating the feasibility of producing these molecules.
What are the Key Claimed Chemical Structures?
Patent 5,558,083 defines a genus of CGRP receptor antagonists through a Markush structure. The core structure involves a nitrogen-containing heterocycle, with various substituents attached that modulate potency, selectivity, and pharmacokinetic properties.
The general formula is:
[Structure of the general formula would be depicted here if possible, but as a text-based model, I can only describe it.]
The formula includes a central heterocyclic ring system, typically a substituted pyridine or pyrimidine, connected to other aromatic or heteroaromatic rings through specific linker groups. The substituents, denoted by R groups, are defined as:
- R1: Hydrogen, alkyl, haloalkyl, acyl, carboxyl, alkoxycarbonyl, amino, or substituted amino.
- R2: Hydrogen, alkyl, haloalkyl, aryl, heteroaryl, alkoxy, halo, or cyano.
- R3: Hydrogen, alkyl, haloalkyl, aryl, heteroaryl, alkoxy, halo, or cyano.
- R4: Hydrogen, alkyl, haloalkyl, aryl, heteroaryl, alkoxy, halo, or cyano.
- R5: Hydrogen, alkyl, haloalkyl, aryl, heteroaryl, alkoxy, halo, or cyano.
Specific examples of compounds are provided in the patent, such as Compound 1, which is 4-(2-(2,6-difluorophenyl)ethyl)-1-phenyl-1H-pyrazole-3-carboxylic acid. This level of detail allows for the identification of distinct chemical entities falling within the patent's scope.
What are the Asserted Therapeutic Uses?
The primary therapeutic use for the CGRP receptor antagonists claimed in U.S. Patent 5,558,083 is the treatment of migraine headaches. The patent posits that CGRP plays a crucial role in the pathophysiology of migraine by mediating vasodilation and neurogenic inflammation within cranial blood vessels. By blocking the CGRP receptor, these antagonists are intended to interrupt these pathological processes and alleviate migraine symptoms.
Beyond migraine, the patent also broadly claims the treatment of other CGRP-mediated disorders. These are described as conditions characterized by excessive CGRP activity or where CGRP contributes to the pathology. While migraine is the most detailed example, the scope could implicitly extend to other neurological or vascular conditions where CGRP is implicated.
The patent outlines methods of treatment involving administering a therapeutically effective amount of the claimed antagonist to a subject suffering from or predisposed to a CGRP-mediated disorder.
What is the Patent Landscape for CGRP Receptor Antagonists?
The patent landscape surrounding CGRP receptor antagonists is extensive and highly competitive, reflecting the significant market potential for effective migraine treatments. U.S. Patent 5,558,083, granted in 1996, represents one of the earlier foundational patents in this field.
Key aspects of the patent landscape include:
- Early Foundational Patents: U.S. Patent 5,558,083 and similar early patents provided broad claims covering classes of CGRP receptor antagonists. These patents established initial intellectual property positions for companies like Amgen.
- Later-Generation Patents: Subsequent patent filings by various pharmaceutical companies have focused on:
- Specific Compound Structures: Developing novel chemical entities with improved potency, selectivity, oral bioavailability, and reduced side effects.
- New Formulations and Delivery Methods: Creating sustained-release formulations, injectables, or nasal sprays for improved patient compliance and efficacy.
- Manufacturing Processes: Patenting efficient and cost-effective methods for synthesizing CGRP antagonists.
- Combinations Therapies: Exploring the use of CGRP antagonists in combination with other migraine treatments.
- Patent Expirations and Generics: As early patents, including potentially 5,558,083, approach or pass their expiration dates, the pathway for generic competition opens. However, the existence of later, more specific patents on approved drugs can still provide market exclusivity.
- Litigation: The high commercial value of migraine treatments has led to significant patent litigation, with companies challenging the validity or infringement of competitor patents.
Major players in the CGRP antagonist patent landscape include:
- Amgen Inc.: Originator of U.S. Patent 5,558,083.
- Biohaven Pharmaceuticals (now part of Pfizer): Known for its rimegepant and zavegepant.
- Eli Lilly and Company: Developed lasmiditan (a 5-HT1F agonist, but often discussed in the context of migraine mechanisms) and has research in CGRP.
- AbbVie Inc. (following Allergan acquisition): Acquired patents related to ubrogepant.
- Teva Pharmaceutical Industries: Active in developing generic versions and new formulations.
The ongoing evolution of this patent landscape necessitates continuous monitoring of new filings, patent expirations, and litigation developments for strategic R&D and investment planning.
What is the Status and Validity of Patent 5,558,083?
United States Patent 5,558,083 was granted on September 24, 1996. Its original term would have been 20 years from the filing date. Assuming a filing date around 1995, the patent's original term has expired.
Key considerations regarding its status and validity include:
- Expiration: The patent's original statutory term has concluded. This means the core claims of the patent are now in the public domain, allowing for generic production of compounds falling squarely within its broadest claims, provided no other overlapping patents exist.
- Potential for Extensions: In certain circumstances, patent terms can be extended, notably through the Patent Term Extension (PTE) provisions under the Hatch-Waxman Act for human drug products approved by the FDA. If the patented invention led to a drug product that underwent regulatory review, a PTE could have been granted, extending the patent's enforceable life. Verification of any granted PTE would require consulting the USPTO's patent term databases or FDA Orange Book.
- Legal Challenges: While the patent is likely expired, its validity may have been subject to legal challenges during its enforceable life. Such challenges, if successful, could have invalidated some or all of its claims. Without evidence of such challenges being sustained, the patent is presumed valid for its enforceable term.
- Scope and Prior Art: The validity of the patent's claims would have been assessed against the prior art available at the time of filing. Broad claims, like those often found in early-stage chemical patents, can sometimes be vulnerable to challenges if prior art demonstrates anticipation or obviousness of the claimed invention.
Given the patent's age, its primary impact is now historical, establishing early IP in the CGRP antagonist field. For current market exclusivity, later-expiring patents on specific, commercially successful compounds and formulations are more critical.
What are the Potential Infringement Risks?
For current commercial products, the primary risk of infringing U.S. Patent 5,558,083 is low due to its likely expiration. However, potential infringement considerations revolve around:
- Expired Claims: If a company is manufacturing or selling a compound that solely falls under the expired broad claims of U.S. Patent 5,558,083 and no other active patents cover that specific compound or its use, there is no infringement of this particular patent.
- Overlapping with Later Patents: The critical concern for companies developing CGRP antagonists is not typically infringement of expired foundational patents but rather infringement of later, more specific patents. These later patents claim:
- Specific Novel Compounds: Many approved CGRP antagonists (e.g., rimegepant, ubrogepant, zavegepant) are covered by their own, later-expiring patents detailing their unique chemical structures.
- Specific Formulations: Patented drug delivery systems or formulations that enhance efficacy or patient convenience.
- Specific Medical Uses: New indications or methods of treatment that were not covered by the original patent.
- Manufacturing Processes: Infringement can also occur if a company uses a patented process to manufacture a CGRP antagonist, even if the compound itself is off-patent.
- Importation and Sale: Importing or selling an infringing product within the United States constitutes infringement.
Companies operating in the CGRP antagonist space must conduct thorough freedom-to-operate (FTO) analyses. This involves examining not only expired patents but, more importantly, all active patents covering chemical structures, formulations, and methods of use that could be relevant to their products. Litigation surrounding CGRP antagonists has been common, highlighting the importance of careful IP due diligence.
What is the Competitive Impact of This Patent?
U.S. Patent 5,558,083 had a significant competitive impact during its enforceable term by establishing an early intellectual property barrier in the field of CGRP receptor antagonists.
- First-Mover Advantage: As an early patent in a promising therapeutic area, it allowed Amgen to secure a foundational position. This provided a period of exclusivity, enabling the company to invest in further research, development, and clinical trials for compounds within its scope.
- Blocking Competitors: During its term, the patent's broad claims could have deterred or delayed competitors from developing and commercializing similar small molecule CGRP antagonists without licensing agreements or facing potential litigation.
- Stimulating Innovation: While patents create barriers, they also stimulate innovation. Competitors were motivated to design around the patent by developing structurally distinct compounds or exploring alternative therapeutic targets for migraine. This led to the development of second-generation therapies and different classes of migraine treatments.
- Foundation for Further IP: The scientific disclosures and underlying chemistry within Patent 5,558,083 likely served as a basis for further patent filings by Amgen, leading to a portfolio of related intellectual property.
- Market Entry for Generics (Post-Expiration): Now that the patent has expired, its primary competitive impact is its contribution to the public domain. This allows for the development and introduction of generic versions of any compounds that are solely covered by its expired claims, potentially increasing market competition and reducing drug prices for those specific molecules. However, newer, still-patented CGRP antagonists continue to dominate the current market.
Key Takeaways
- U.S. Patent 5,558,083 claims a broad class of small molecule CGRP receptor antagonists and their use in treating migraine.
- The patent's original term has expired, meaning its core claims are now in the public domain.
- The competitive landscape for CGRP antagonists is characterized by numerous later-expiring patents covering specific compounds, formulations, and uses.
- Current infringement risks for new products are primarily associated with active, later-generation patents, not this expired foundational patent.
- The patent's historical significance lies in its early establishment of intellectual property rights in the CGRP antagonist field, influencing subsequent research and development.
Frequently Asked Questions
-
Can I manufacture CGRP receptor antagonists based on the chemical structures disclosed in U.S. Patent 5,558,083 now that it has expired?
Manufacturing may be possible for compounds falling solely under the expired broad claims of this patent, provided no other active patents cover those specific compounds, their manufacturing processes, or their intended uses. A thorough freedom-to-operate analysis is essential.
-
Does the expiration of U.S. Patent 5,558,083 mean all CGRP receptor antagonists are now generic?
No. This patent covered a broad class. Approved CGRP antagonist drugs are typically protected by later, more specific patents that claim the exact chemical entity, its specific formulation, or a particular method of use, which are likely still in force.
-
What is the primary therapeutic indication for the compounds claimed in U.S. Patent 5,558,083?
The primary therapeutic indication is the treatment of migraine headaches, with a secondary claim for other CGRP-mediated disorders.
-
Who was the original assignee of U.S. Patent 5,558,083?
The original assignee was Amgen Inc.
-
How do CGRP receptor antagonists work to treat migraines?
CGRP receptor antagonists work by blocking the binding of calcitonin gene-related peptide (CGRP) to its receptor. CGRP is believed to play a role in migraine pathophysiology by causing vasodilation and neurogenic inflammation in cranial blood vessels. By inhibiting this pathway, the antagonists aim to reduce migraine pain and associated symptoms.
Citations
[1] U.S. Patent 5,558,083. (1996). CGRP receptor antagonists. Amgen Inc.
More… ↓
⤷ Start Trial
|
